OOIR: Observatory of International Research

Papers

(The TQCC of Multiple Sclerosis Journal is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Mitochondrial measures in neuronally enriched extracellular vesicles predict brain and retinal atrophy in multiple sclerosis	192
Depression is a core symptom of multiple sclerosis: No	79
DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity – Yes	59
Pseudocystic inflammatory demyelinating lesions in multiple sclerosis: A clinical, radiological, and pathological description	57
Erratum to “Ofatumumab-induced severe reactivation of psoriasis in a patient with multiple sclerosis” Multiple Sclerosis Journal; 2024: 30(8); 1086–1088. DOI: 10.1177/13524585241260564.	53
Presymptomatic MS or radiologically isolated syndrome should be actively monitored and treated: Commentary	53
ACTRIMS Forum 2021 – Invited Program	51
Inclusion of optic neuritis in dissemination in space improves the performance of McDonald 2017 criteria in Hispanic people with suspected multiple sclerosis	50
The future for non-pharmacological treatments in MS: Looking back and moving forward	48
Optic chiasm involvement in multiple sclerosis, aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein–associated disease	48
Utilising multi-large omics data to elucidate biological mechanisms within multiple sclerosis genetic susceptibility loci	47
Thematic analysis of multiple sclerosis research by enhanced strategic diagram	44
Reliability of paramagnetic rim lesion detection at 1.5T MRI in multiple sclerosis patients	42
Well-being at midlife: Correlates of mental health in ambulatory menopausal women with multiple sclerosis	42
Two years of COVID-19 in the MS community: What have we learnt so far?	41
Time to move past typical syndromes in the diagnosis of multiple sclerosis	41
Therapy challenges for NMOSD in a patient with HIV	39
The role of body fat in multiple sclerosis susceptibility and severity: A Mendelian randomisation study	39
The Finger Dexterity Test: Validation study of a smartphone-based manual dexterity assessment	39
Diagnostic performance of central vein sign versus oligoclonal bands for multiple sclerosis	38
Sars-CoV2 infection in pregnant women with multiple sclerosis	38
Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial	37
A closer look at reported colitis in association with multiple sclerosis treatments	36
Severe febrile neutropenia associated with satralizumab in an Argentinian NMOSD patient—Commentary	35
Impact of clinical outcomes and imaging measures on health-related quality of life in secondary progressive MS	34

Risk of depression and anxiety in multiple sclerosis and neuromyelitis optica spectrum disorder: A nationwide cohort study in South Korea	33
Longitudinal evaluation of serum MOG-IgG titers in MOGAD after initiation of maintenance immunoglobulin: A case series	32
Depression readmission risk is elevated in multiple sclerosis compared to other chronic illnesses	31
From discovery to replication: Power and definitions matter for multiple sclerosis severity	31
Artificial intelligence will change MS care within the next 10 years: No	31
Evaluating the efficacy and safety of transitioning patients with multiple sclerosis from natalizumab to ocrelizumab (OCTAVE)	31
Do isolated cognitive relapses exist? Yes	30
Ofatumumab-induced severe reactivation of psoriasis in a patient with multiple sclerosis	30
Misdiagnosis in multiple sclerosis in a Brazilian reference center: Clinical, radiological, laboratory profile and failures in the diagnostic process—Cohort study	29
Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system	28
Neurophysiological MEG markers of cognitive impairment and performance validity in multiple sclerosis	27
A proposed new taxonomy of cognitive phenotypes in multiple sclerosis: The International Classification of Cognitive Disorders in MS (IC-CoDiMS)	27
Final analysis of 379 pregnancy outcomes after exposure to dimethyl fumarate in a prospective international registry	27
Employment status, productivity loss, and associated factors among people with multiple sclerosis	27
ECTRIMS 2021 Committees	26
Neuropsychological assessment in MS is outdated and is in need for innovation: Yes	26
Anti-CGRP therapies for migraine in multiple sclerosis patients	26
Safety of COVID-19 vaccines in multiple sclerosis: A systematic review and meta-analysis	26
Expansion of chronic MS lesions is associated with an increase of radial diffusivity in periplaque white matter	25
Therapy with mesenchymal stem cell transplantation in multiple sclerosis is ready for prime time: No	24
Quality of life is decreased in persons with relapsing-remitting multiple sclerosis experiencing progression independent of relapse activity	24
Incidence of optic neuritis among Afro-descendant, a cohort study	24
Safety of anti-varicella zoster virus vaccination in patients with multiple sclerosis treated with natalizumab: A case series	24
An aggressive form of MOGAD treated with aHSCT: A case report	23
Serum MOG-IgG titers should be performed routinely in the diagnosis and follow-up of MOGAD: No	23
Cerebrospinal fluid–related tissue damage in multiple sclerosis patients with iron rim lesions	23
Longitudinally extensive posterolateral myelitis revealing invasive CNS aspergillosis in an immunocompetent patient	23
Reply to letter to the editor: Olfactory threshold as a biomarker of disease activity	22
Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment	22
A role for HLA in mediating long-term multiple sclerosis outcomes?	22
Demyelinating disorders following COVID-19 vaccination	22
ECTRIMS 2022 – ePoster	22
Accuracy of serum neurofilament light to identify contrast-enhancing lesions in multiple sclerosis	22
MSMilan2023 – LB Paper Posters – Session 2	21
Epstein-Barr virus infection in patients with MOGAD	21
Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentum	21
Gait stability reflects motor tracts damage at early stages of multiple sclerosis	21
ACTRIMS Forum 2022- Poster Presentations	21
The era of harmonised disability outcomes in multiple sclerosis	20
Phonemic processing is below expectations and linked to word-finding difficulty in multiple sclerosis	20
Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions	20
Effectiveness of immunotherapies in relapsing myelin oligodendrocyte glycoprotein antibody-associated disease	20
All Bruton’s tyrosine kinase inhibitors have similar efficacy and risks: No	19
Relapsing tumefactive demyelination: time to recognize a distinct demyelinating condition?	19
Time-varying connectivity of the precuneus and its association with cognition and depressive symptoms in neuromyelitis optica: A pilot MRI study	18
Testing for myelin oligodendrocyte glycoprotein antibodies: Who, what, where, when, why, and how	18
Productivity loss among people with early multiple sclerosis: A Canadian study	18
The health-related quality of life of children with multiple sclerosis is mediated by the health-related quality of life of their parents	18
Olfactory threshold as a biomarker of disease activity	18
Progressive motor impairment from “critical” demyelinating lesions of the cervicomedullary junction	18

ACTRIMS Forum 2023 Author Index	17
Long-term clinical, MRI, and cognitive follow-up in a large cohort of pathologically confirmed, predominantly tumefactive multiple sclerosis	17
Anti-SARS-CoV-2 monoclonal antibodies for the treatment of active COVID-19 in multiple sclerosis: An observational study	17
Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: Post hoc analysis of the TEMSO core and extension studies	17
MSMilan2023 – ePoster	17
RIMS abstracts 2021: Table of Contents by Submission Group	17
Association between infections, the microbiome, vaccination, and neuromyelitis optica spectrum disorder	17
Natalizumab reduces loss of gray matter and thalamic volume in patients with relapsing-remitting multiple sclerosis: A post hoc analysis from the randomized, placebo-controlled AFFIRM trial	17
MSMilan2023 – LB Paper Posters – Session 1	17
Natalizumab concentrations during pregnancy in three patients with multiple sclerosis	17
ECTRIMS 2021 – ePoster	16
Addressing LGBTQ+ health equity and disparities in multiple sclerosis: A call for research and action	16
Paradigm shifts: Early initiation of high-efficacy disease-modifying treatment in multiple sclerosis	16
Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study	16
Physical and psychological aspects of multiple sclerosis: Revisiting the Multiple Sclerosis Impact Scale (MSIS-29)	16
Cortical ischemic lesions from atrial myxoma as a mimic of disease activity in an RRMS antiCD20-treated patient	16
All Bruton’s tyrosine kinase inhibitors have similar efficacy and risks: Yes	16
Serum MOG-IgG in children meeting multiple sclerosis diagnostic criteria	16
Exosomal profiling should be used to monitor disease activity in MS patients: Yes	15
MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses – Commentary	15
Estimation of sample size in randomized controlled trials in multiple sclerosis studying annualized relapse rates: A systematic review	15
GM-CSF is a marker of compartmentalised intrathecal inflammation in multiple sclerosis	15
Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study	15
Long-term trajectories of employment status, workhours and disability support pension status, after a first episode of CNS demyelination	15
Physical exercise in multiple sclerosis is not just a symptomatic therapy, it has a disease-modifying effect: Commentary	15
Arterial stiffness in persons with multiple sclerosis and controls: Does aerobic fitness account for group differences?	15
Creating an automated tool for a consistent and repeatable evaluation of disability progression in clinical studies for multiple sclerosis	15
MSMilan2023 – Paper Poster - Session 1	15
ACTRIMS Forum 2024, February 29 – March 2, 2024, West Palm Beach, Florida	14
The current state of diversity, equity, and inclusion in multiple sclerosis research, clinical trials, and workforce	14
The effect of national disease-modifying therapy subsidy policy on long-term disability outcomes in people with multiple sclerosis	14
Cognitive phenotypes predict response to restorative cognitive rehabilitation in multiple sclerosis	14
Natalizumab concentrations during pregnancy in three patients with multiple sclerosis: A clinical commentary	14
Keep your eyes on the prize: Tackling breakthrough COVID-19 in MS patients	14
Coexistence of multiple sclerosis and spinocerebellar ataxia type-8	14
Relapsing meningitis and limbic encephalitis in anti-AQP4-Ab-associated neuromyelitis optica spectrum disorder	14
Responsiveness to pembrolizumab in severe early-onset natalizumab associated PML-IRIS in patient with relapsing-remitting multiple sclerosis	14
Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study	14
Exposure to systemic antibiotics in outpatient care and the risk of multiple sclerosis	14
Central vein sign and other radiographic features distinguishing myelin oligodendrocyte glycoprotein antibody disease from multiple sclerosis and aquaporin-4 antibody-positive neuromyelitis optica	14
Multiple sclerosis presenting with paroxysmal symptoms: Patients at the limitations of current diagnostic criteria	13
Progression independent of relapse activity in multiple sclerosis: Time to account for cognitive decline	13
ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs	13
Cognition in patients with neuromyelitis optica spectrum disorders: A prospective multicentre study of 217 patients (CogniNMO-Study)	13
COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022	13
Seizure history and cognitive dysfunction in people with multiple sclerosis	13
Imposter clinical trials or answering questions with observational data	13
Eculizumab treatment during pregnancy in a patient with AQP4-IgG-seropositive NMOSD: A case report	13
Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results	13
A disproportionality analysis for the association of central nervous system demyelinating diseases with COVID-19 vaccination using the World Health Organization pharmacovigilance database	13
Evaluation of the predictive value of CSF-restricted oligoclonal bands on residual disability and risk of relapse in adult patients with MOGAD: MOGADOC study	13
Radiologically isolated syndrome in the spectrum of multiple sclerosis	13
Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS	13
Evaluation of arterial spin labeling in the diagnosis and monitoring of myelin oligodendrocyte glycoprotein-associated cerebral cortical encephalitis	13
High prevalence of comorbidities at diagnosis in immigrants with multiple sclerosis	13
An interdisciplinary approach is necessary in the treatment of cognitive decline in MS: No	13
Presymptomatic MS or radiologically isolated syndrome should be actively monitored and treated: Yes	13
Multiple Sclerosis Cognitive Scale (MSCS): A brief psychometrically robust metric of patient-reported cognitive difficulty	13
A smartphone sensor-based digital outcome assessment of multiple sclerosis	12
Communication deficits in multiple sclerosis: Interactions with cognitive dysfunction and their impact on employment status	12
Paramagnetic rim lesions predict greater long-term relapse rates and clinical progression over 10 years	12
Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study	12
Pregnancy and multiple sclerosis: 2022 recommendations from the French multiple sclerosis society	12
Stretching is not essential for managing MS spasticity: A randomized controlled trial	12
A new look at cognitive functioning in pediatric MS	12
Susceptibility-based imaging aids accurate distinction of pediatric-onset MS from myelin oligodendrocyte glycoprotein antibody-associated disease	12
A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment	12
Serum neurofilament light-chain levels in children with monophasic myelin oligodendrocyte glycoprotein-associated disease, multiple sclerosis, and other acquired demyelinating syndrome	12
The MoxFo initiative – outcomes: Outcome measures in studies of exercise training in multiple sclerosis; scoping review of reviews and classification according to the ICF framework	12
The timed 25-foot walk in a large cohort of multiple sclerosis patients	12
Choroid plexus volume is enlarged in clinically isolated syndrome patients with optic neuritis	11
Association of daily physical activity with brain volumes and cervical spinal cord areas in multiple sclerosis	11
Prevalence, co-occurrence, and trajectories of pain, fatigue, depression, and anxiety in the year following multiple sclerosis diagnosis	11
Teriflunomide in pediatric patients with relapsing multiple sclerosis: Open-label extension of TERIKIDS	11
Low socioeconomic status was associated with a higher mortality risk in multiple sclerosis	11
Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study	11
Double-negative neuromyelitis optica spectrum disorder	11
Eighteen-month safety analysis of offspring breastfed by mothers receiving glatiramer acetate therapy for relapsing multiple sclerosis – COBRA study	11
Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?	11
Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity	11

The MoXFo initiative – study design: Considerations related to study design and methodology in exercise research for people with multiple sclerosis	11
Hand functioning in progressive multiple sclerosis improves with tDCS added to daily exercises: A home-based randomized, double-blinded, sham-controlled clinical trial	11
Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing: NO	11
Prediction of relapse activity when switching to cladribine for multiple sclerosis	11
Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension	11
Decentralised clinical trials in multiple sclerosis research	11
Vaccination in multiple sclerosis: Tackling challenges and paving the way for effective immunization	11
Paramagnetic rim lesions are associated with greater incidence of relapse and worse cognitive recovery following relapse	11
Cognitive dysfunction and mortality in multiple sclerosis: Long-term retrospective review	10
Neuroaxonal damage in natalizumab-treated MS patients: The role of JCV antibody titres	10
Peripheral helper T cells in the pathogenesis of multiple sclerosis	10
Retinal layer thinning for monitoring disease-modifying treatment in relapsing multiple sclerosis—Evidence for applying a rebaselining concept	10
Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study	10
Physical exercise in multiple sclerosis is not just a symptomatic therapy, it has a disease-modifying effect: No	10
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis	10
Facial pain in MS: When to think of trigeminal autonomic cephalalgia	10
Artificial intelligence applied to MRI data to tackle key challenges in multiple sclerosis	10
Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk: No	10
Serious side effects of amantadine: Rethinking the benefits and risks of medications for MS fatigue	10
Disease progression in the first 5 years of treatment in multiple sclerosis: Predictive value of early brain and lesion volume changes	10
Intrathecal immune reactivity against Measles-, Rubella-, and Varicella Zoster viruses is associated with cerebrospinal fluid inflammation in multiple sclerosis	10
Optical coherence tomography versus other biomarkers: Associations with physical and cognitive disability in multiple sclerosis	10
Retinal small vessel pathology is associated with disease burden in multiple sclerosis	9
Letter to the editor: Mobile health interventions in multiple sclerosis: A systematic review	9
Functional and structural MRI correlates of executive functions in multiple sclerosis	9
The time to include cognition in the multiple sclerosis concept of progression independent from relapse activity is now	9
ECTRIMS 2022 LB Poster	9
Impact of COVID-19 vaccination or infection on disease activity in a radiologically isolated syndrome cohort: The VaxiRIS study	9
T1/T2-weighted ratio is a surrogate marker of demyelination in multiple sclerosis—yes	9
Migraines, the multiple sclerosis prodrome, and multiple sclerosis susceptibility	9
Personalized monitoring of ambulatory function with a smartphone 2-minute walk test in multiple sclerosis	9
Cortical involvement and leptomeningeal inflammation in myelin oligodendrocyte glycoprotein antibody disease: A three-dimensional fluid-attenuated inversion recovery MRI study	9
Characterization of multiple sclerosis neuroinflammation and neurodegeneration with relaxation and diffusion basis spectrum imaging	9
ACTRIMS Forum 2022- Invited Program	9
Managing patients with late-onset neutropenia during treatment with ocrelizumab	9
Low-dose rituximab should be used for treating MS in resource-limited settings: No	9
Genetic and early life factors influence on time-to-multiple sclerosis diagnosis: A UK Biobank study	9
Rituximab and pregnancy: Late-onset neutropenia in a 2-month infant whose mother received rituximab 2 weeks prior to childbirth	9
Low transfer of cladribine into human milk	9
Race and ethnicity in multiple sclerosis phase 3 clinical trials: A systematic review	9
To halt disease progression rehabilitation in MS should start early: Yes	8
The value of patient-reported outcome measures for multiple sclerosis	8
Epilepsia Partialis Continua as a manifestation of aquaporin-4 autoimmunity	8
Low-dose rituximab should be used for treating MS in resource-limited settings: Commentary	8
MSMilan 2023 – ePoster	8
Climate change and multiple sclerosis: Clinical challenges and strategies	8
Detecting isolated cognitive relapses in persons with MS	8
Rectifying global inequities in neuromyelitis optica diagnosis and treatment	8
How to avoid missing a diagnosis of neuromyelitis optica spectrum disorder	8
Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk: Commentary	8
Toward a holistic approach to multiple sclerosis: The role of social determinants of health	8
Performance validity in outpatients with multiple sclerosis and cognitive complaints	8
Corrigendum for Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial	8
The disease-modifying therapy utilisation and cost trend for multiple sclerosis in Australia between 2013 and 2022	8
Pseudocystic demyelination in multiple sclerosis	8
The impact of relapse definition and measures of durability on MS clinical trial outcomes	8
Validation of an obstructive sleep apnea symptom inventory in persons with multiple sclerosis	8
DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity – No	8
Multiple sclerosis diagnosis: Knowledge gaps and opportunities for educational intervention in neurologists in the United States	8
Acute urticaria following ofatumumab injection for multiple sclerosis	7
Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years	7
Neoehrlichiosis associated with ocrelizumab in a patient with multiple sclerosis: A case report	7
MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses – No	7
Prevalence and incidence of multiple sclerosis in Turkey: A nationwide epidemiologic study	7
The clinical spectrum of haemorrhagic CNS inflammatory demyelinating lesions	7
BCG vaccination and multiple sclerosis risk: A Norwegian cohort study	7
No evidence for association between rs10191329 severity locus and longitudinal disease severity in 1813 relapse-onset multiple sclerosis patients from the MSBase registry	7
Neurofilament in clinical practice: Is the multiple sclerosis community ready?	7
Body mass index as a predictor of MS activity and progression among participants in BENEFIT	7
Anti-CD20 therapy in pregnancy: Balancing risks and benefits	7
Healthcare utilization in multiple sclerosis: Impact of disease modifying therapies and comorbidities	7
Eye movement desensitization and reprocessing for depressed individuals with multiple sclerosis: A pilot study	7
Trends in central nervous system-active polypharmacy among people with multiple sclerosis	7
Corrigendum	7
Social determinants of health and disparate disability accumulation in a cohort of Black, Hispanic, and White patients with multiple sclerosis	7
Risk of multiple sclerosis in individuals with infectious mononucleosis: a national population-based cohort study using hospital records in England, 2003–2023	7
Polypharmacy in multiple sclerosis: More is not necessarily better	7
Leptomeningeal enhancement on post-contrast FLAIR images for early diagnosis of Susac syndrome	7
Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing–remitting MS	7
All anti-CD20 monoclonal antibodies have similar efficacy and risks: Commentary	7
Intimate partner violence and multiple sclerosis	7
Mobility trajectories in multiple sclerosis: A comparative study of timed 25-foot walk and a patient-reported outcome measure	7
Stability of the gut microbiota in persons with paediatric-onset multiple sclerosis and related demyelinating diseases	7
Altered functional brain states predict cognitive decline 5 years after a clinically isolated syndrome	7
Impact of COVID-19 on pregnancy and fetal outcomes in women with multiple sclerosis	7
Disease-modifying therapies enter the World Health Organization Essential Medicines List: A victory now requiring a roadmap of implementation	7
Mobile health interventions in multiple sclerosis: Bringing empowerment into clinical practice	7
MOG-antibody-associated longitudinal extensive myelitis after ChAdOx1 nCoV-19 vaccination	7
Multiple sclerosis can be diagnosed solely with dissemination in space: No	7
ACTRIMS Forum 2022 Author Index	7
Multiple sclerosis and cancer: Navigating a dual diagnosis	7